Skip to main content

Gestión clínica personalizada del paciente oncológico con insuficiencia renal aguda (IRA) asociada a inhibidores de puntos de control inmunitarios (ICIs)

AC22/00035

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Subprogram Subprograma Estatal de Internacionalización
Call Proyectos de Colaboracion Internacional
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD POLITECNICA DE CATALUÑA
Execution centre UNIVERSIDAD POLITECNICA DE CATALUÑA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Rossell, Joana|||0000-0003-1500-6379
  • Alonso, N.
  • Weber, R.J.M.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Lloyd, G.R.
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Winder, Catherine|||0000-0002-1648-5255
  • Junza, Alexandra
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: Disruption of lipid metabolism contributes to increased cardiovascular risk in diabetes. Methods: We evaluated the associations between serum lipidomic profile and subclinical carotid atherosclerosis (SCA) in type 1 (T1D) and type 2 (T2D) diabetes, and in subjects without diabetes (controls) in a cross-sectional study. All subjects underwent a lipidomic analysis using ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry, carotid ultrasound (mode B) to assess SCA, and clinical assessment. Multiple linear regression models were used to assess the association between features and the presence and burden of SCA in subjects with T1D, T2D, and controls separately. Additionally, multiple linear regression models with interaction terms were employed to determine features significantly associated with SCA within risk groups, including smoking habit, hypertension, dyslipidaemia, antiplatelet use and sex. Depending on the population under study, different confounding factors were considered and adjusted for, including sample origin, sex, age, hypertension, dyslipidaemia, body mass index, waist circumference, glycated haemoglobin, glucose levels, smoking habit, diabetes duration, antiplatelet use, and alanine aminotransferase levels. Results: A total of 513 subjects (151 T1D, 155 T2D, and 207 non-diabetic control) were included, in whom the percentage with SCA was 48.3%, 49.7%, and 46.9%, respectively. A total of 27 unique lipid species were associated with SCA in subjects with T2D, in former/current smokers with T2D, and in individuals with T2D without dyslipidaemia. Phosphatidylcholines and diacylglycerols were the main SCA-associated lipidic classes. Ten different species of phosphatidylcholines were up-regulated, while 4 phosphatidylcholines containing polyunsaturated fatty acids were down-regulated. One diacylglycerol was down-regulated, while the other 3 were positively associated with SCA in individuals with T2D without dyslipidaemia. We discovered several features significantly associated with SCA in individuals with T1D, but only one sterol could be partially annotated. Conclusions: We revealed a significant disruption of lipid metabolism associated with SCA in subjects with T2D, and a larger SCA-associated disruption in former/current smokers with T2D and individuals with T2D who do not undergo lipid-lowering treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data

  • Manzini, E.|||0000-0003-2961-5335
  • Vlacho, Bogdan|||0000-0003-3768-8112
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Escudero, J.
  • Génova, A.
  • Reixach, Elisenda|||0000-0001-8557-0771
  • Andrés, E.
  • Pizarro, I.
  • Mauricio, Didac|||0000-0002-2868-0250
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
Recent evidence indicates that Type 2 Diabetes Mellitus (T2DM) is a complex and highly heterogeneous disease involving various pathophysiological and genetic pathways, which presents clinicians with challenges in disease management. While deep learning models have made significant progress in helping practitioners manage T2DM treatments, several important limitations persist. In this paper we propose DARE, a model based on the transformer encoder, designed for analyzing longitudinal heterogeneous diabetes data. The model can be easily fine-tuned for various clinical prediction tasks, enabling a computational approach to assist clinicians in the management of the disease. We trained DARE using data from over 200,000 diabetic subjects from the primary healthcare SIDIAP database, which includes diagnosis and drug codes, along with various clinical and analytical measurements. After an unsupervised pre-training phase, we fine-tuned the model for predicting three specific clinical outcomes: i) occurrence of comorbidity, ii) achievement of target glycemic control (defined as glycated hemoglobin <7%) and iii) changes in glucose-lowering treatment. In cross-validation, the embedding vectors generated by DARE outperformed those from baseline models (comorbidities prediction task AUC=0.88, treatment prediction task AUC=0.91, HbA1c target prediction task AUC=0.82). Our findings suggest that attention-based encoders improve results with respect to different deep learning and classical baseline models when used to predict different clinical relevant outcomes from T2DM longitudinal data.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus

  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Weber, Ralf J.M.|||0000-0002-8796-4771
  • Lloyd, Gavin R.|||0000-0001-7989-6695
  • Hernandez, Marta
  • Yanes, Oscar|||0000-0003-3695-7157
  • Capellades, Jordi|||0000-0002-6502-8202
  • Jankevics, Andris|||0000-0003-2095-6846
  • Winder, Catherine|||0000-0002-1648-5255
  • Falguera, Mireia|||0000-0002-7846-8952
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Dunn, Warwick B.|||0000-0001-6924-0027
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Mauricio, Didac|||0000-0002-2868-0250
Background: In this study, we evaluated the lipidome alterations caused by type 1 diabetes (T1D) and type 2 diabetes (T2D), by determining lipids significantly associated with diabetes overall and in both sexes, and lipids associated with the glycaemic state. Methods: An untargeted lipidomic analysis was performed to measure the lipid profiles of 360 subjects (91 T1D, 91 T2D, 74 with prediabetes and 104 controls (CT)) without cardiovascular and/or chronic kidney disease. Ultra-high performance liquid chromatography-electrospray ionization mass spectrometry (UHPLC-ESI-MS) was conducted in two ion modes (positive and negative). We used multiple linear regression models to (1) assess the association between each lipid feature and each condition, (2) determine sex-specific differences related to diabetes, and (3) identify lipids associated with the glycaemic state by considering the prediabetes stage. The models were adjusted by sex, age, hypertension, dyslipidaemia, body mass index, glucose, smoking, systolic blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, alternate Mediterranean diet score (aMED) and estimated glomerular filtration rate (eGFR); diabetes duration and glycated haemoglobin (HbA1c) were also included in the comparison between T1D and T2D. Results: A total of 54 unique lipid subspecies from 15 unique lipid classes were annotated. Lysophosphatidylcholines (LPC) and ceramides (Cer) showed opposite effects in subjects with T1D and subjects with T2D, LPCs being mainly up-regulated in T1D and down-regulated in T2D, and Cer being up-regulated in T2D and down-regulated in T1D. Also, Phosphatidylcholines were clearly down-regulated in subjects with T1D. Regarding sex-specific differences, ceramides and phosphatidylcholines exhibited important diabetes-associated differences due to sex. Concerning the glycaemic state, we found a gradual increase of a panel of 1-deoxyceramides from normoglycemia to prediabetes to T2D. Conclusions: Our findings revealed an extensive disruption of lipid metabolism in both T1D and T2D. Additionally, we found sex-specific lipidome changes associated with diabetes, and lipids associated with the glycaemic state that can be linked to previously described molecular mechanisms in diabetes.